86361-55-9
86361-55-9 結構式
基本信息
2,6,3',5'-四羥基二苯乙烯
Gnetol>
-2-(3,5-Dihydroxystyryl)
2,3',5',6-Tetrahydroxy-trans-stilbene
(E)-2-(3,5-Dihydroxystyryl)benzene-1,3-diol
2-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol
2-[(1E)-2-(3,5-Dihydroxyphenyl)ethenyl]-1,3-benzenediol
1,3-Benzenediol, 2-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]-
2-[(1E)-2-(3,5-Dihydroxyphenyl)ethenyl]-1,3-benzenediol USP/EP/BP
物理化學性質
常見問題列表
|
COX-1 0.78 μM (IC 50 ) |
Tyrosinase 4.5 μM (IC 50 ) |
HDAC
|
The antiproliferative activities of Gnetol are tested in HCT-116, Hep-G2, MDA-MB-231, and PC-3 cell lines by measuring cell viability after treatment with 4.1 μM, 40.9 μM, 204.7 μM, 409.4 μM, and 1023.6 μM. Gnetol shows concentration-dependent reductions in cell viability in cancer cell lines with greatest activity in colorectal cancer.
Gnetol at 200 μg/mL significantly offers the highest protection of 54.3% against the toxicant. A lower dose of Gnetol (50 μg/mL) also shields the cell line from the toxic effects of CCl4.
The ligand molecule TGF-β and PPARα protein show that Gnetol has the binding affinity of 7.0 and 8.4, respectively.
Male Sprague-Dawley rats were cannulated and dosed either intravenously with Gnetol (10?μg/kg) or orally (100?mg/kg). After oral and intravenous administration, Gnetol is detected in both serum and urine as the parent compound and as a glucuronidated metabolite. The bioavailability of Gnetol is determined to be 6%. Gnetol is rapidly glucuronidated and is excreted in urine and via nonrenal routes.
Pretreatment of Male NIH Swiss mice (20-35 g) with Gnetol (50mg/kg, SC) is able to increase the latency period to response in analgesia models.